Synulox
Disclaimer: This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Synulox but is not affiliated with or related to the manufacturer of Synulox and the contents of this site are neither sponsored or endorsed by the manufacturer of Synulox.
Buy Synulox
Introduction
1. Synulox Palatable Tablets 50 mg and 250 mg
2. Synulox Palatable Tablets 500 mg
3. Synulox Ready-to-use Suspension for Injection
4. Synulox Palatable Drops
5. Synulox Bolus 500 mg film-coated tablet
6. Synulox Lactating Cow Intramammary Suspension
Presentation
1. Synulox Palatable Tablets 50 mg and 250 mg
Synulox Palatable Tablets are presented as circular, pink tablets with a break line on one face and `SYNULOX' engraved on the other. Each tablet contains clavulanic acid as potassium clavulanate and amoxicillin as Amoxicillin trihydrate in a palatable base. The composition of the two tablet sizes is as follows:
50 mg
40 mg amoxicillin and 10 mg clavulanic acid.
250 mg
200 mg amoxicillin and 50 mg clavulanic acid.
2. Synulox Palatable Tablets 500 mg
Synulox Palatable Tablets are presented as circular, pink tablets with a break line on one face and `SYNULOX' engraved on the other. Each tablet contains 100 mg clavulanic acid as potassium clavulanate and 400 mg amoxicillin as Amoxicillin trihydrate in a palatable base.
3. Synulox Ready-to-use Suspension for Injection
Synulox Ready-To-Use Suspension for Injection is an off-white suspension containing 35 mg/ml clavulanic acid as Potassium clavulanate and 140 mg/ml amoxicillin as Amoxicillin trihydrate.
4. Synulox Palatable Drops
Synulox Palatable Drops are presented in a bottle as an off-white powder, containing 150 mg potassium clavulanate equivalent to clavulanic acid and 600 mg Amoxicillin trihydrate equivalent to amoxicillin. Reconstitution of the powder with 15 ml of water provides a suspension containing 10mg clavulanic acid and 40mg amoxicillin per ml.
5. Synulox Bolus 500 mg film-coated tablet
Synulox Bolus 500 mg film-coated tablets are presented as large, pink, film-coated, bolus-shaped tablets, with a break line on one side and 'SYNULOX' engraved on the other. Each bolus contains 100 mg clavulanic acid as potassium clavulanate and 400 mg amoxicillin as Amoxicillin trihydrate.
6. Synulox Lactating Cow Intramammary Suspension
Synulox Lactating Cow Intramammary Suspension is a pale cream/buff coloured oily suspension containing clavulanic acid, amoxicillin and prednisolone in a non-irritant base designed to disperse rapidly in milk. It is presented in syringes containing 50 mg of clavulanic acid as Potassium clavulanate, 200 mg of amoxicillin as Amoxicillin trihydrate and 10 mg of Prednisolone in 3 g of suspension.
Uses
1. Synulox Palatable Tablets 50 mg and 250 mg
Synulox Palatable Tablets have a notably broad spectrum of bactericidal activity against bacteria commonly found in cats and dogs.
In vitro Synulox is active against a wide range of clinically important aerobic and anaerobic bacteria including:
Gram-positive: | Staphylococci (including β-lactamase producing strains); Clostridia; Corynebacteria; Peptostreptococcus spp; Streptococci. |
Gram-negative: | Bacteroides spp (including β-lactamase producing strains); Escherichia coli (including most β-lactamase producing strains); Salmonellae (including β-lactamase producing strains); Bordetella bronchiseptica; Campylobacter spp; Fusobacterium necrophorum; Klebsiellae; Pasteurellae; Proteus spp. |
Clinically Synulox has been shown to be effective in treating a wide range of diseases of cats and dogs including: Skin disease (including deep and superficial pyodermas); soft tissue infections (abscesses and anal sacculitis); dental infections (eg gingivitis); urinary tract infections; respiratory disease (involving upper and lower respiratory tract); enteritis.
2. Synulox Palatable Tablets 500 mg
| Synulox Palatable Tablets 500 mg Uses Synulox Palatable Tablets have a broad spectrum of activity against bacteria commonly found in dogs. In vitro Synulox is active against a wide range of clinically important aerobic and anaerobic bacteria, including:
Clinically, Synulox has been shown to be effective in treating a wide range of diseases of dogs including: Skin disease (including deep and superficial pyoderma); urinary tract infection; respiratory disease involving upper and lower respiratory tract, enteritis, dental infections (e.g. gingivitis), soft tissue infections (e.g. abscesses and anal sacculitis). Note: Synulox is not indicated for cases involving Pseudomonas spp. 3. Synulox Ready-to-use Suspension for Injection Synulox Ready-To-Use Suspension for Injection has a notably broad spectrum of bactericidal activity against the bacteria commonly found in cattle, pigs and small animals. 1.(a) In vitro Synulox is active against a wide range of clinically important bacteria including: Gram-positive:Staphylococci (including beta-lactamase producing strains), Streptococci, Corynebacteria, Clostridia, Bacillus anthracis, Actinomyces bovis, Peptostreptococcus spp. Gram-negative: Actinobacillus pleuropneumoniae, Escherichia coli (including beta-lactamase producing strains),Salmonellae (including beta-lactamase producing strains), Bordetella bronchiseptica, Campylobacter spp., Klebsiellae, Proteus spp., Pasteurellae, Fusobacterium necrophorum, Bacteroides (including beta-lactamase producing strains), Haemophilus spp., Moraxella spp. and Actinobacillus lignieresi. 2.Clinically, Synulox has been shown to be effective in treating a wide range of diseases including: Cattle: -Respiratory infections -Soft tissue infections (e.g. joint/navel ill, abscesses etc.) -Metritis -Mastitis Pigs: -Respiratory bacterial infections in growing pigs -Colibacillosis -Periparturient infections in sows (eg mastitis, metritis and agalactia.) Dogs and cats: -Respiratory tract infections -Urinary tract infections -Skin and soft tissue infections (e.g. abscesses, pyoderma, anal sacculitis and gingivitis). 4. Synulox Palatable Drops Synulox Palatable Drops have a notably broad spectrum of bactericidal activity against bacteria commonly found in dogs and cats. In vitro Synulox is active against a wide range of clinically important aerobic and anaerobic bacteria including:
Clinically Synulox has been shown to be effective in treating a wide range of diseases of cats and dogs including: Skin disease (including deep and superficial pyodermas); soft tissue infections (abscesses and anal sacculitis); dental infections (eg gingivitis); urinary tract infections; respiratory disease (involving upper and lower respiratory tract); enteritis. 5. Synulox Bolus 500 mg film-coated tablet Synulox boluses have a notably broad spectrum of bactericidal activity against bacteria commonly found in calves. In vitro Synulox is active against a wide range of clinically important bacteria including:
The clinical indications for Synulox boluses are in the treatment of enteritis and navel ill in calves. 6. Synulox Lactating Cow Intramammary Suspension Synulox Lactating Cow is specially formulated for the treatment of bovine mastitis. It has a notably broad spectrum of bactericidal activity against the bacteria commonly isolated from the bovine udder. The prednisolone in Synulox Lactating Cow has an anti-inflammatory action which helps to reduce the potentially destructive swelling and inflammation associated with mastitis, without affecting the white cell response to infection. In vitro Synulox is active against a wide range of clinically important bacteria, including the following organisms, which are commonly associated with bovine mastitis: Staphylococci (including beta-lactamase-producing strains), Streptococci (including S. agalactiae, S. dysgalactiae and S. uberis), A. pyogenes and other minor members of the Corynebacteria spp. Escherichia coli (including beta-lactamase producing strains). In addition, it is active in vitro against many less common udder pathogens including: Bacillus cereus, Bacteroides (including β-lactamase producing strains) Campylobacter spp., Klebsiellae and Pasteurellae. Clinically, Synulox Lactating Cow has been shown to be an effective routine treatment for mastitis in lactating cows. Cases responding successfully to treatment include infections with the following major pathogens: Staphylococci (including β-lactamase producing strains), Streptococci (including S. agalactiae, S. dysgalactiae, and S. uberis), Escherichia coli (including β-lactamase-producing strains). |
Dosage & administration
1. Synulox Palatable Tablets 50 mg and 250 mg
Administration
By the oral route. Synulox palatable tablets are often accepted from the hand even by sick cats and dogs. Alternatively, the tablets may be crushed and added to a little food.
Dosage rate
12.5 mg/kg bodyweight.
Dosage frequency
The following table is intended as a guide to dispensing Synulox Palatable Tablets at the standard dose rate of 12.5 mg/kg, twice daily.
For the majority of infections, including those of the skin, urinary tract and gastrointestinal tract, the above dosing regime is effective.
Refractory cases, however, particularly those of the respiratory tract, have shown improved cure rates by doubling the dose to 25 mg/kg bodyweight twice daily. (Note that the smallest animals of 1 kg bodyweight when dosed with ½ tablet will already be receiving the doubled (25 mg/kg) dose rate.)
Duration of therapy
Routine cases involving all indications: The majority of these cases respond to between 5 and 7 days therapy.
Number of tablets per dose, twice daily | ||
Bodyweight (kg) | 50 mg | 250 mg |
1– 2 | ½ | — |
3– 5 | 1 | — |
6– 9 | 2 | — |
10–13 | 3 | — |
14–18 | 4 | — |
19–25 | — | 1 |
26–35 | — | 1½ |
36–49 | — | 2 |
50 | — | 3 |
Chronic or refractory cases
In these cases, where there is considerable tissue damage, a longer course of therapy may be required in that it allows sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:
Chronic skin disease | 10–20 days |
Chronic cystitis | 10–28 days |
Respiratory disease | 8–10 days |
2. Synulox Palatable Tablets 500 mg
Administration
By the oral route.
Dosage Guide
Recommended dose rate is 12.5 mg/kg, twice daily. The table below is intended as a guide only.
Bodyweight (kg) | Number of Tablets per dose Twice Daily |
500 mg | |
20 kg | ½ |
40 kg | 1 |
60 kg | 1½ |
80 kg | 2 |
For oral administration only. Synulox Palatable Tablets are often accepted from the hand, even by sick dogs. Alternatively, the tablets may be crushed and added to a small quantity of food. The majority of routine cases will respond between 5 and 7 days therapy. Because of the low toxicity profile of Synulox, the dose can be doubled if desired at the discretion of the veterinary surgeon for severe infection. In certain indications, for example canine pyoderma and chronic cystitis, bacterial infection may be secondary to other pathology. For such cases longer courses of antibacterial therapy may be required, in addition to diagnosis and treatment of the underlying condition. In such circumstances overall treatment length must be at the clinician's discretion, but should be long enough to ensure complete resolution of the bacterial disease.
3. Synulox Ready-to-use Suspension for Injection
The recommended dosage rate is 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid), equivalent to 1 ml of suspension per 20 kg bodyweight.
Treatment should be administered once daily for 3 to 5 days.
Shake the vial well before use. Inject by the subcutaneous or intramuscular route in dogs and cats, and by the intramuscular route only in cattle and pigs. After injection, massage the injection site.
The suspension is not suitable for intravenous or intrathecal administration. Great care should be taken to avoid contaminating the remaining contents of the vial with water (see 'Pharmaceutical precautions').
Combined therapy for the treatment of bovine mastitis: In the situation where systemic treatment as well as intramammary treatment is necessary, Synulox Ready-to-Use Suspension for Injection can be administered in combination with Synulox Lactating Cow Intramammary Suspension using the following minimum treatment regime:
Synulox RTU | Synulox LC |
8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight and then 24 hours later | One syringe gently infused into the teat of the infected quarter and then 12 hours later One syringe gently infused into the teat of the infected quarter and then 12 hours later |
8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight and then 24 hours later 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight Where necessary, Synulox RTU Injection may be administered for an additional two days for a total of 5 daily injections. | One syringe gently infused into the teat of the infected quarter |
4. Synulox Palatable Drops
Administration
By the oral route.
Reconstitution
Add 15ml water. Shake the bottle before use.
Dosage rate
12.5 mg/kg bodyweight (i.e. 0.25 ml/kg). For the accurate dosing of particularly small patients it is valuable to note that one drop from the pipette provided contains 2.3 mg clavulanate-potentiated amoxicillin. Therefore 5–6 drops/kg twice daily are recommended as a guide.
Dosage frequency
Dogs and cats should be dosed at the rate of 0.25 ml of reconstituted product per kg bodyweight twice daily.
For the majority of infections, including those of the skin, urinary tract and gastrointestinal tract, the above dosing regime is effective.
Refractory cases, however, particularly those of the respiratory tract, have shown improved cure rates by doubling the dose to 25 mg/kg bodyweight twice daily (i.e. 0.5 ml of reconstituted product per kg bodyweight twice daily).
Duration of therapy
Routine cases involving all indications
The majority of these cases respond to between 5 and 7 days therapy.
Chronic or refractory cases
In these cases, where there is considerable tissue damage, a longer course of therapy may be required in that it allows sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:
Chronic skin disease | 10–20 days |
Chronic cystitis | 10–28 days |
Respiratory disease | 8–10 days |
5. Synulox Bolus 500 mg film-coated tablet
Administration
By the oral route.
Dosage rate
6.25–12.5 mg/kg bodyweight twice daily, e.g. a 40 kg calf will require ½ bolus twice daily, but this may be doubled in cases of severe infection.
Treatment should be continued for up to 12 hours after the clinical signs have subsided to a maximum of 3 days of treatment.
6. Synulox Lactating Cow Intramammary Suspension
Dosage
A course of 3 syringes per affected quarter–one syringe every 12 hours.
Administration
After milking, clean and disinfect the teat end thoroughly with surgical spirit. Insert the syringe nozzle into the teat orifice and apply gentle and continuous pressure until the suspension is expressed. The treated quarter(s) may be milked out at the next normal milking time, but the milk should be discarded.
Combined Therapy for the treatment of bovine mastitis. In the situation where systemic treatment as well as intramammary treatment is necessary, Synulox Ready-To-Use Injection can be administered in combination with Synulox Lactating Cow Intramammary using the following minimum treatment regime.
Synulox RTU | Synulox LC |
8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight and then 24 hours later | One syringe gently infused into the teat of the infected quarter and then 12 hours later One syringe gently infused into the teat of the infected quarter and then 12 hours later |
8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight and then 24 hours later 8.75 mg/kg bodyweight (7.0 mg amoxicillin, 1.75 mg clavulanic acid) i.e. 1 ml/20 kg bodyweight Where necessary, Synulox RTU Injection may be administered for an additional two days for a total of 5 daily injections. | One syringe gently infused into the teat of the infected quarter |
Price comparison
Contra-indications, warnings, etc.
1. Synulox Palatable Tablets 50 mg and 250 mg
For animal treatment only. Synulox Palatable Tablets should not be given to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in their use in any other very small herbivores.
Operator warning
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reaction to cephalosporins and vice-versa. Allergic reaction to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations. Wash hands after use.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms, and may require urgent medical attention.
2. Synulox Palatable Tablets 500 mg
In common with other penicillins, Synulox should not be administered orally to rabbits, guinea pigs hamsters or gerbils, and should be used with care in other small herbivores.
Synulox should not be administered concomitantly with bacteriostatic antibiotics, which are incompatible.
Operator warning
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reaction to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and may require urgent medical attention.
In the event of accidental ingestion, seek medical advice.
Wash hands after handling the tablets.
For animal use only.
Keep out of the reach of children.
3. Synulox Ready-to-use Suspension for Injection
In common with all other penicillins, Synulox should not be administered to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in its use in any other very small herbivores.
Use of the product may occasionally result in pain on injection and/or local tissue reaction.
Operator warnings
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing, are more serious symptoms and require urgent medical attention.
Wash hands after use.
Withholding times
Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken only from cows after 60 hours from the last treatment.
Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 42 days from the last treatment. Pigs 4. Synulox Palatable Drops
Synulox Palatable Drops should not be given to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in their use in any other very small herbivores.
Operator warning
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice-versa. Allergic reaction to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and may require urgent medical attention.
Wash hands after use.
5. Synulox Bolus 500 mg film-coated tablet
Animals must not be slaughtered for human consumption for 9 days following the last treatment.
Do not use in animals with known sensitivity to the active ingredients.
In common with other penicillins, the product should not be administered orally to rabbits, guinea pigs, hamsters or gerbils.
The combination is of a low order of toxicity and is well tolerated by the oral route. Limited overdose normally produces no adverse effects.
Operator warning
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reaction to cephalosporins and vice-versa. Allergic reaction to these substances may occasionally be serious.
1.Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
2.Handle this product with great care to avoid exposure, taking all recommended precautions. Wash hands after use.
3.If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and may require urgent medical attention.
6. Synulox Lactating Cow Intramammary Suspension
During the course of treatment the situation should be reviewed frequently by close veterinary supervision.
Milk for human consumption must not be taken from a cow during treatment. With cows milked twice daily, milk for human consumption may only be taken from 60 hours (i.e. at the 5th milking) after the last treatment.
Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 7 days from the last treatment.
With other milking routines, the basis of the veterinary surgeon's advice should be that milk may be taken for human consumption only after the same period from the last treatment (e.g. with three times a day milking and the product administered twice per day, milk for human consumption may only be taken at the 6th milking).
Combined Therapy: When using Synulox LC Intramammary and Synulox RTU in combination, animals must not be slaughtered for human consumption during treatment. Cows may not be slaughtered for human consumption until 42 days after the last treatment. Milk must not be taken for human consumption during treatment. Milk for human consump-tion may be taken only from cows after 60 hours from the last treatment of Synulox RTU following the minimum dosage regime described in Dosage and Administration.
Operator warnings
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing, are more serious symptoms and require urgent medical attention.
Wash hands after use.
Pharmaceutical precautions
1. Synulox Palatable Tablets 50 mg and 250 mg
Do not store above 25°C. Store in a dry place. Keep out of the reach of children.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
2. Synulox Palatable Tablets 500 mg
Do not store above 25°C. Store in a dry place.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
3. Synulox Ready-to-use Suspension for Injection
Do not store above 25°C. Keep out of the reach of children. For animal treatment only.
This product does not contain an antimicrobial preservative. Following withdrawal of the first dose, use the product within 28 days. Discard unused material.
Swab the septum before removing each dose.
Clavulanic acid is moisture sensitive. It is very important, therefore, that a completely dry needle and syringe is used when extracting suspension for injection in order to avoid contaminating the remaining contents of the vial with drops of water.
Contamination will result in obvious beads of dark brown discolouration corresponding to the introduced water droplets. Material affected in this way should not be used as it may have significantly reduced potency.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
4. Synulox Palatable Drops
Powder: Do not store above 25°C.
Reconstituted suspension: Store at 2-8°C. Any reconstituted suspension remaining 7 days after preparation should be discarded.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Keep out of reach of children.
For animal treatment only.
5. Synulox Bolus 500 mg film-coated tablet
Do not store above 25°C. Store in a dry place.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
6. Synulox Lactating Cow Intramammary Suspension
Store in a dry place. Do not store above 25°C.
Keep out of the reach of children. For animal treatment only.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Legal Category: POM-V
Packaging quantities
1. Synulox Palatable Tablets 50 mg and 250 mg
Both size tablets are packed in foil strips containing 5×2 tablets. 50 mg tablets are supplied in packs of 100 and 500, 250 mg tablets are in packs of 100 and 250.
2. Synulox Palatable Tablets 500 mg
Laminated aluminium foil packs with 2 tablets in each blister card. Packed in an outer carton box and marketed as a 100 tablet presentation.
3. Synulox Ready-to-use Suspension for Injection
Packs containing 6 x 100 ml and 12 x 40 ml vials.
4. Synulox Palatable Drops
Synulox Palatable Drops are supplied in bottles containing 15ml of product following reconstitution (equivalent to 750 mg of clavulanate-potentiated amoxicillin). A dropper with graduations of 0.25 ml, up to 1 ml, is included in each pack to ensure accurate, convenient dosing.
5. Synulox Bolus 500 mg film-coated tablet
Packs containing 20 and 100 boluses.
6. Synulox Lactating Cow Intramammary Suspension
Cartons of 12 and 24 syringes.
Further information
1. Synulox Palatable Tablets 50 mg and 250 mg
Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Synulox counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the organisms sensitive to amoxicillin's rapid bactericidal effect, at concentrations readily attainable in the body.
Synulox is effective against Klebsiella infections found in veterinary practice, but it is not indicated for cases involving Pseudomonas species.
Synulox Palatable Tablets are often accepted from the hand, even by sick dogs and cats. Alternatively, the tablets may be crumbled and added to a little food.
Synulox Palatable Tablets can safely be used during pregnancy and lactation.
Synulox Palatable Drops are available as an alternative presentation for treating small individuals.
2. Synulox Palatable Tablets 500 mg
Amoxicillin is a broad-spectrum antibiotic active against a wide range of Gram-positive and Gram-negative bacteria. However, many clinically important bacteria produce beta-lactamase enzymes which destroy this antibiotic. Clavulanic acid inactivates these enzymes, rendering the organisms susceptible to the amoxicillin.
Synulox Palatable Tablets can safely be used in pregnant and lactating animals
3. Synulox Ready-to-use Suspension for Injection
Synulox is a novel concept in antibiotic therapy.
Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Synulox counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the bacteria sensitive to amoxicillin’s rapid bactericidal effect, at concentrations readily attainable in the body.
Synulox is effective against Klebsiella infections found in veterinary practice, but it is not indicated for cases involving Pseudomonas species.
Synulox RTU may be used in pregnant animals, subject to observance of the withholding time for milk and meat intending for human consumption.
4. Synulox Palatable Drops
Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Synulox counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the organisms sensitive to amoxicillin's rapid bactericidal effect, at concentrations readily attainable in the body.
Synulox is effective against Klebsiella infections found in veterinary practice, but it is not indicated for cases involving Pseudomonas species.
Synulox Palatable Drops can be safely used in pregnant and lactating animals.
Synulox Palatable Tablets are available as an alternative presentation for treating sick dogs and cats.
5. Synulox Bolus 500 mg film-coated tablet
Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Synulox counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the organisms sensitive to amoxicillin's rapid bactericidal effect.
Synulox is effective against Klebsiella infections found in veterinary practice, but it is not indicated for cases involving Pseudomonas species.
6. Synulox Lactating Cow Intramammary Suspension
Synulox is a novel concept in antibiotic therapy. Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Synulox counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the bacteria sensitive to amoxicillin's rapid bactericidal effect, at concentrations readily attainable in the udder.
Synulox is effective against Klebsiella infections found in veterinary practice, but it is not indicated for cases involving Pseudomonas species.
Disclaimer
This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Synulox but is not affiliated with or related to the manufacturer of Synulox and the contents of this site are neither sponsored or endorsed by the manufacturer of Synulox.